Advertisement

Weibliche Gonaden

  • C. v. Hagens
  • U. Heinrich
  • F. Kiesewetter
  • T. Rabe
  • B. Runnebaum
  • E. Schulze
  • E. Vladescu

Zusammenfassung

Der Hypothalamus spielt als Relaisstation (Umsetzer) eine wichtige Rolle zur Transformation elektrischer Impulse des ZNS in biochemische Signale (sog. Releasing-Hormone: GnRH, CRF, GHRF, TRH und Somatostatin), die durch Neurosekretion über den Hypophysenstiel zur Hypophyse transportiert werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Abschn. 5.7 bis 5.6

  1. Adashi E. (1997) Menstrual cyele: Follicular maturation. In: Rabe T., Runnebaum B. (eds) Manual on assisted reproduction. Springer, Berlin Heidelberg Tokyo New York, p 12–21Google Scholar
  2. Breckwoldt M., Keck C., (1997) Pubertät und Adoleszenz. In: Keck C., Neulen J., Breckwoldt M. (Hrsg) Endokrinologie, Reproduktionsmedizin, Andrologie. Thieme, StuttgartGoogle Scholar
  3. Gerhard I., Heinrich U. (1994) Die Pubertät und ihre Störungen. In Runnebaum B., Rabe T. (Hrsg) Gynäkologische Endokrinologie und Fortpflanzungsmedizin. Bd 1, Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  4. Gerhard I., Runnebaum B. (1994) Endokrinologie der Frühschwangerschaft. In: Runnebaum B., Rabe T. (Hrsg) Gynäkologische Endokrinologie und Fortpflanzungsmedizin. Bd 2, Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  5. Gougeon A. (1986) Dynamics of follicular growth in the human: a model from preliminary results. Human Reprod 1:81–87Google Scholar
  6. Grunewald K., Rabe T., Runnebaum B. (1994) Physiologie des menstruellen Zyklus. In: Runnebaum B., Rabe T. (Hrsg) Gynäkologische Endokrinologie und Fortpflanzungsmedizin. Bd 1, Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  7. Grunwald K., Rabe T., Runnebaum B. (1997) Physiology of the menstrual cyele. In: Rabe T., Runnebaum B. (eds) Manual on assisted reproduction. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  8. Kelch R.P., Beitins I.Z. Adolescent sexual development. In: Kappy M.S., Blizzard R.M., Migeon C.J. (eds) Wilkins: The diagnosis and treatment of endocrine disorders in childhood and adolescence. 4th edn, Thomas, Springfield, IL, p 193Google Scholar
  9. Schmitt-Mathiesen H., Hepp H. (1998) Gynäkologie und Geburtshilfe. Schattauer, StuttgartGoogle Scholar
  10. Tanner J.M. (1975) Growth and endocrinology of the adolescent, in: Gardner L.: Endocrine and Genetic Diseases of Childhood. Saunders, Philadelphia LondonGoogle Scholar

Literatur zu Absch. 5.7

  1. Clayton R.N. (1997) Symptoms, signs and long-term outcomes of adulthood acquired hypopituitarism. In: Lamberts S.W.J. (ed) The diagnosis and Treatment of pituitary deficiency. Bristol, BioScientifica, pp 3–16Google Scholar
  2. European and Australian Multicentre Study (1995) Co-treatment with growth hormone and gonadotropin for induction of ovulation in hypogonadotropic patients: a prospective, randomized, placebo-controlled dose respond study. Fertil Steril 64: 917–923Google Scholar
  3. Gromoll J., Simoni M., Nordhoff V., Behre H.M., de Geyter C., Nieschlag E. (1996) Functional and clinical consequences of mutations in the FSH receptor. Mol-Cell-Endocrinol 125: 177–182PubMedGoogle Scholar
  4. Gromoll J., Simoni M., Nieschlag E. (1996) An activating mutation of the follicle-stimulatung hormone rezeptor autonomously sustains spermatogenesis in a hypophysectomized man. J Clin Endocrinol Metab 81: 1367–70PubMedGoogle Scholar
  5. Hardelin J.E., Petit C. (1995) A molecular approach to the pathophysiology of the X-Iinked Kallmann’s syndrome. Bailliere’ s Clin Endocrinol Metab 9: 489Google Scholar
  6. Jänicke F., Rjosk H.K., Berg, D., Gioning K. (1983) Pulsatile GnRH-Substitution beim Kallmann-Syndrom der Frau. Geburtshilfe Frauenheilkd 43: 351–354PubMedGoogle Scholar
  7. Knoll J.H.M., Cheng S.D., LaLande M.(1994) Allele specificity of DNA replication timing in the Angelman/Prader-Willi syndrome imprinte chromosomal region. Nature Genet 6: 41–46PubMedGoogle Scholar
  8. Lamberts S.W.J., de Herder W.W., van der Lely A.J. (1998) Pituitary insufficiency. Lancet 352Google Scholar
  9. Leyendecker G., Wildt L. (1983) Induction of ovulation with chronic intermittent (pulsatile) administration of GnRH in women with hypothalamic amenorrhoea. J Reprod Fertil 69: 397PubMedGoogle Scholar
  10. Paff D.W. et al. (1982) GnRH neurons and other cellular molecular mechanisms for simple mammalian reproductive secretion. Acta abstet gynecol scand 61: 439–443Google Scholar
  11. Petit, C. (1993)Molecular basis of the X-chromosome-linked Kallmann’s Syndrome. Trends Endocrinol Metab 4: 8PubMedGoogle Scholar
  12. Wood D.F., Franks S. (1998) Hypogonadism in women. In: Grossman A. (ed) Clinical endocrinology. Blackwell Scientific Publications, Oxford, pp 702–717Google Scholar

Literatur zu Abschn. 5.8

  1. Bierich J.R., Burgmann G., Kiessling E. (1989) The spontaneous secretion of GH during nocturnal sleep. Monatsschr Kinderhlk 137: 80Google Scholar
  2. Brown D.C., Stirling H.F., Butler G.E., Kelnar C.J., Wu F.C. (1996) Differentiation of normal male prepuberty and hypogonadotrophic hypogonadism using an ultrasensitive luteinizing hormone assay. Horm Res 46: 83–87PubMedGoogle Scholar
  3. Crowne E.C., Shalet S.M., Wallace W.H.B., Eminson D.M., Price D.A. (1991) Final height in girls with untreated CDGP. Eur J Pediatr 150: 708–712PubMedGoogle Scholar
  4. De la Chapelle A. (1983) Sex chromosome abnormalities. In: Emery A.E.H., Rimoin D.L. (eds) Principles and practice of medical genetics. Vol. I. Churchill Livinstone, Edinburgh, pp 193–215Google Scholar
  5. Haavisto A.M., Dunkel L., Petterson K., Huhtaniemi I.(1990) LH measurements by in vitro bioassay and a highly sensitive immunofluorometric assay improve the distinction beetween boys with constitutional delay of puberty and hypogonadotropic hypogonadism. Pediatr Res 27: 211–214PubMedGoogle Scholar
  6. Hook E.B., Warburton D. (1983) The distribution of chromosomal genotypes associated with Turner’s syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural x abnormalities of mosaicism. Hum Genet 64: 24–27PubMedGoogle Scholar
  7. Nyborg H., Nielson J. (1977) Sex chromosomal abnormalities and cognitive performance: III Field dependence, frame dependence, and failing development of perceptual stability in girls with Turner’s syndrome. J Psychol 96: 205PubMedGoogle Scholar
  8. Rosenfeld R.G., Attie K.M., Frane J. et al. (1998) Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr 132: 319–324PubMedGoogle Scholar
  9. Stanhope R., Hindmarsh P., Pringle P.J., Holownia P., Honour J., Brook C.G.D. (1987) Oxondralone in duces a sustained rise in physiological growth hormone secretion in boys with constitutional delay of growth and puberty. Pediatrician 14: 183PubMedGoogle Scholar
  10. Waber D.P. (1979) Neuropsychological aspects of Turner’s syndrome. Develop Med Child Neurol 21: 58–70PubMedGoogle Scholar
  11. Waldstreicher J., Seminara S.B., Jameson J.L. et al. (1996) The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. J Clin Endocrinol Metab 81: 4388–4395PubMedGoogle Scholar

Literatur zu Abschn. 5.9

  1. Bettendorf G. (1976) Zum Problem der Gonadotropinbehandlung. Geburtshilfe Frauenheilkd 36: 1017Google Scholar
  2. Cates W., Farley T.M.M., Rowe P.J. (1985) Worldwide pattern of infertility: is Africa different? Lancet, p 596–598Google Scholar
  3. Collet M., Reniers J., Frost E. et al. (1988) Infertility in Central Africa; infection is the cause. Int J Gynaecol Obstet 26/3: 423–428Google Scholar
  4. Daya S. (1989) Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet gynaecol 96: 275–280PubMedGoogle Scholar
  5. Goldstein P., Berrier J., Rosen S., Sacks H.S., Chalmers T.C. (1989) A meta-aanalysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 96: 265–274PubMedGoogle Scholar
  6. Graf M.A., Fischer R. (1996) Diagnostik und Therapie beim ovariellen Hyperstimulationssyndrom. Gynäkologe 29: 300Google Scholar
  7. Insler V., Melmed H., Lunenfeld B. (1972) The cervical score. Int J Gynecol Obstet 10: 223Google Scholar
  8. Kaiser R., Daume E., Lang N. (1968) Ovulationsauslösung mit Clomiphen und Gonadotropin. Med Wochensch 47: 1Google Scholar
  9. Lehmann F., Breckwoldt M. (1991) Gonadotropine: drei Jahrzehnte Entwicklung. HMG-Behandlung in der Praxis. Enke, Stuttgart (Bücherei des Frauenarztes Bd 39)Google Scholar
  10. Leyendecker G., Wildt L. (1983) Induction of ovulation with chronic intermittent (pulsatile) administration of GnRH in women with hypothalamic amenorrhoea. J Reprod Fertil 69: 397PubMedGoogle Scholar
  11. Lunenfeld B., Insler V., Glezerman M. (1992) Diagnosis and treatment of functional infertility, Blackwell, BerlinGoogle Scholar
  12. Rudolf K., Martens E., Hofmann R., Rüting M. (1993) Ergebnisse der Behandlung der funktionellen Sterilität mit Clomiphen. Zentralbl Gynakol 105: 193Google Scholar
  13. Schenker J.G., Yarkoni S., Granat M. (1981) Multiple pregnancies following induction of ovulation. Fertil Steril 35: 105PubMedGoogle Scholar
  14. Thonneau P., Spira A. (1990) Prevalence of infertility: international data and problems of measurement. Eur J obstet gynecol Reprod Biol 38/1:43–52Google Scholar

Literatur zu Abschn. 5.10

  1. Barret-Connor E., Bush T.L. (1991) östrogen and coronary heart disease in women. J Am Med Assoc 265: 1861–1867Google Scholar
  2. Christiansen C., Christiansen M.S., Transböl I.(1981) Bone mass in postmenopausal women after withdrawal of oestrogenl ge stagen replacement therapy. Lancet 1: 459–461PubMedGoogle Scholar
  3. Collaborative Group on Hormonal Factors in Breast Cancer (1997). Lancet 350: 1047–59Google Scholar
  4. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348: 977–980PubMedGoogle Scholar
  5. Editorial (1995) START beschreibt Aspekte der AlzheimerKrankheit: Ärztliche Hilfe für Demenzkranke. START 3: 6–18Google Scholar
  6. Grodstein F., Stampfer M.J., Goldhaber S.Z. et al. (1996) Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348: 983–987PubMedGoogle Scholar
  7. Hemminki E., McPherson K. (1997) Impact ofpostmenopausalhormone therapy on cardiovascularevents and cancer: pooled data from clinical trials. BMJ 315: 149–53PubMedGoogle Scholar
  8. Henderson V.W. (1998a) Östrogens and prevention of Alzheimer’s disease. The Management of the Menopause. Annual Review, Parthenon, London, pp 183–192Google Scholar
  9. Henderson V.W. (1998b) Sexualsteroide und Alzheimer-Krankheit: Therapeutische Überlegungen. In: ESKA (eds) S. 51–60 (IV. Europäischer Menopausen Kongress, Wien)Google Scholar
  10. Hillard T.C., Whitehead M.I. (1991) Hormon Substitutionstherapie-Wege der Verabreichung. In: Medical Communications Services (Hrsg) Kardiovasculäre Wirkungen einer Hormon Substitutionstherapie. Proceedings Internationales Novo Nordisk Symposium Kopenhagen, Dänmark, 1.-2. Februar 1991Google Scholar
  11. Hollihn U.K. (1997) The climacteric-a period of transition. Hormone Replacement Therapy and the Menopause, pp 12–107; ScheringGoogle Scholar
  12. Hulley S. et al. (1998) Randomized Trial of Ostrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA 280: 605–613PubMedGoogle Scholar
  13. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 348: 981–983PubMedGoogle Scholar
  14. Kannel W.B., Hjortland M.C., Mcnamara P.M., Gordon T. (1976) Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85(4)Google Scholar
  15. Lilly (1998) Produktinformation EVISTAGoogle Scholar
  16. Potthoff P. et al. (2000) The Menopause Rating Scale (MRS II): methodological standardization in the German population. Zentralbl Gynakol 122(5): 280–6PubMedGoogle Scholar
  17. Rabe T., Grunwald K., Vladescu E., Runnebaum B. (1998) Kardiovaskuläres Risiko und Hormonersatztherapie. Der Gynäkologe 10(31):859–869Google Scholar
  18. Runnebaum B., Rabe T., Holst T. von, Wüster C. (1994) Klimakterium der Frau. In: Runnebaum B., Rabe T. (eds) Gynäkologische Endokrinologie und Reproduktionsmedizin, Bd 1, Springer, Berlin Heidelberg New York Tokyo, S 513–588Google Scholar
  19. Sarrel P. (1989) Effects of ovarian steroids on the cardiovascular system. In: Ginsburg J. (ed) The circulation of the female. Parthenon, Carnforth, New Jersey, pp 117–140Google Scholar
  20. Schiff I., Komarov Sela H., Cramer D., Tulchinsky D., Ryan K.J. (1982) Endometrial hyperplasia in women on cyclic or continuous es trogen regimens. Fertil Steril 37: 79–82PubMedGoogle Scholar
  21. Smith-Bindmann R. et al. (1998) JAMA 280: 1510–1517Google Scholar
  22. Swales J.D. (1996) Cardiovascular complications and the menopause. In: Messerli F.H. (ed) (1996) Hypertension in postmenopausal women, Dekker, pp 139–148Google Scholar
  23. Holst T. von(1982) Hormonelle Diagnostik im Klimakterium der Frau. Habilitationsschrift, Ruprecht-Karls-Universitä ts-HeidelbergGoogle Scholar
  24. Whitehead M.I. (1986) Prevention of endometrial abnormalities. Acta Obstet Gynecol Scand Suppl 134: 81–91Google Scholar

Literatur zu Abschn. 5.77

  1. Anasti J.N., Flack M.R., Froehlich J., Nelson L.M., Nisula B.C. (1995) A potential novel mechanism for precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab 80: 276–279PubMedGoogle Scholar
  2. Balducci R., Boscherini B., Mangianlini A., Morellini M., Toscano V. (1994) Isolated precocious pubarche: an approach. J Clin Endocrinol Metab 79: 582PubMedGoogle Scholar
  3. Blanco-Garcia M., Evain-Brian D., Roger M., Job J.C. (1985) Isolated menses in prepubertal girls. Pediatrics 76: 43PubMedGoogle Scholar
  4. Crowley W.F., Comite F., Vale W., Rivier J., Loriaux D.L., Cutler G.B. (1981) Therapeutic use for pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrin Metab 52: 370Google Scholar
  5. Feuillan P.P., Forster C.M., Pescowitz O.H. (1986) Treatment of precocious puberty in the McCune Albright syndrome with the aromatase inhibitor testolactone. New Engl J Med 315: 1115PubMedGoogle Scholar
  6. Freni-Titulaer L.W., Cordero J.F., Haddock L., Lebron G., Martinez R., Mills J.L. (1986) Premature thelarche in Puberto Rico. Am J Dis Child 140: 1263PubMedGoogle Scholar
  7. Garibaldi L.R., Picco P., Magier S., Chevli R., Aceto T. (1991) Serum luteinizing hormone concentrations, as measured by a sensitive immunoradiometric assay in children with normal precocious and delayed pubertal development.J Clin Endocrinol Metab 72: 888PubMedGoogle Scholar
  8. Ibanez L., Potau N., Virdis R. et al. (1993) Postpubertal outcome in girls diagnosed of premature pub arche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76: 1599PubMedGoogle Scholar
  9. Ilicki A., Lewin R.P., Kauli R., Kaufman H., Schachter A., Laron Z. (1984) Premature thelarche-maternal history and sex hormone secretion in 68 girls. Acta Paediatr Scand 73: 756PubMedGoogle Scholar
  10. Kauli R., Galatzer A., Kornreich L., Lazar L., Pertzelan A., Laron Z. (1997) Final height of girls with central precocious pub erty untreated vs. treated with cyproterone acetate or GnRH analogue. A comperative study with reevaluation of predictions by the Bayley-Pinneau method. Horm Res 47(2):54–61PubMedGoogle Scholar
  11. Korth-Schütz S., Levine L.S., New M.I. (1976) Dehydroepiandrosterone sulfate (DS) levels, a rapid test for abnormal adrenal androgen secretion. J Clin Endocrinol Metab 42: 1005PubMedGoogle Scholar
  12. Lee P.A., Dop C. van, Migeon C. (1986) McCune Albright Syndrome: longterm follow up. JAMA 256: 1980Google Scholar
  13. Lee P.A. (1994) Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med 148: 369PubMedGoogle Scholar
  14. Manasco P.K., Pescowitz O.H., Hill S.C., Jones J.M., Barnes K.M., Hench K.D., Loriaux D.L., Cutler G.B. (1989) Six year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious puberty. J Pediatr 115: 105PubMedGoogle Scholar
  15. Marshall W.A., Tanner J.M. (1969) Variations in the pattern of pubertal changes in girls. Arch Dis Child 44: 291–296PubMedGoogle Scholar
  16. Nelson K.G. (1983) Premature thelarche in children born prematurely. J Pediatr 103: 756PubMedGoogle Scholar
  17. Oostdijk W., Rikken B., Schreuder S. et al. (1996) Final height in central precocious puberty after long term treatment with slow release GnRH agonist. Arch Dis Child 75: 292–297PubMedGoogle Scholar
  18. Rosenfield R.L. (1994) Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs. J Pediatr 124: 989–991PubMedGoogle Scholar
  19. Saggese G., Bertelloni S., Baroncelli G.I., Battini R., Franchi G. (1993) Reduction of bone density: an effect of gonadotropin releasing hormone agonist treatment in central precocious puberty. Eur J Pediatr 152: 7 AGoogle Scholar
  20. Sippell W.G., Partsch C.J., Hümmelink R., Lorenzen F. (1992) Langzeittherapie mit dem Retard-LHRH-Agonisten Decapeptyl-Depot bei Mädchen mit Pubertas praecox vera. Ergebnisse einer internationalen Multizenterstudie. Gynäkologe 24: 108Google Scholar
  21. Temeck J.W., Pang S., Nelson C., New M.I. (1987) Genetic defects of steroidogenesis in premature pub arche. J Clin Endocrinol Metab 64: 609PubMedGoogle Scholar
  22. Weinstein L.S., Shenker A., Gejman P.V., Merino M.J., Friedman E., Spiegel A.M. (1991) Activating mutations ofthe stimulating G-protein in the McCune Albright Syndrome. New Engl J Med 325: 1688PubMedGoogle Scholar

Literatur zu Abschn. 5.72

  1. Baron J. (1974) Diagnostik und Therapie des Hirsutismus. Zentralb Gynakol 5: 129–142Google Scholar
  2. Bruchowsky N. (1979) Molekulare Wirkung von Androgenen und Antiandrogenen, 7-21. In: Hammerstein J., LachnitFixon U., Neumann F., Plewig G. (Hrsg) Androgenisierungserscheinungen bei der Frau. 1. Aufl, Excerpta Medica, Amsterdam, S 7–21Google Scholar
  3. Ferriman D., Gallwey J.D. (1961) Clinical assessement of body ha ir growth in women. J Clin Endocr 21: 1440–1447PubMedGoogle Scholar
  4. Grunwald (1998) Persönliche MitteilungenGoogle Scholar
  5. Leidenberger F. (1997) Klinische Endokrinologie für Frauenärzte. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  6. Rosenfield R.L. (1971) Plasma testosterone binding globulin and indexes of the concentration of unbound plasma androgens in normal and hirsute females. J Clin Endocrinol 32: 717–728Google Scholar
  7. Rabe T., Runnebaum B. (1994) Funktionsteste und Untersuchungsmethoden in der gynäkologischen Endokrinologie und Fortpflanzungsmedizin. In: Runnebaum B., Rabe T. (Hrsg) Gynäkologische Endokrinologie und Fortpflanzungsmedizin, Springer, Berlin Heidelberg new York Tokyo, S 29–98Google Scholar
  8. Rabe T., Grunwald K., Runnebaum, B. (1994) Androgenisierungserscheinungen bei der Frau. In: Runnebaum B., Rabe T. (Hrsg.) Gynäkologische Endokrinologie, Springer, Berlin Heidelberg New York Tokyo, S 589–665Google Scholar

Literatur zu Abschn. 5.73

  1. Blanche H., Vexiau P., Clauin S. et al. (1997) Exhaustive screening of the 21-hydroxylase gene in a population of hyperandrogenic women. Hum Genet 101: 56–60PubMedGoogle Scholar
  2. Dörr H.G., Schulze E. (1998) Das adrenogenitale Syndrom. Gynäkologe 31: 539–548Google Scholar
  3. Dörr H.G., Sippell W.G., Willig R.P. (1992) Pränatale Therapie und Diagnostik des adrenogenitalen Syndroms mit 21-Hyxdroxylasedefekt. Mschr Kinderheilkd 140: 661–663Google Scholar
  4. Geley S., Kapelari K. et al. (1996) CYP11B1 mutations causing congenital adrenal hyperplasia due to 11 ß-hydroxylase deficiency. J Clin Endocr Metab 81: 2896–2901PubMedGoogle Scholar
  5. Hughes I.A., Dyas J., Robinson J., Walker R.F., Fahmy D.R. (1985) Monitoring treatment in congenital adrenal hyperplasia. Use of serial measurements of 17-OH-progesterone in plasma, capillary blood, and saliva. Ann NY Acad Sci 458: 193–202PubMedGoogle Scholar
  6. Jaresch S., Komely E., Kley H.K., Schlaghecke R. (1992) Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocr Metab 74: 685–689PubMedGoogle Scholar
  7. Laue L., Merke D.P., Jones J.V., Bames K.M., Hili S., Cutler G.B. Jr. (1996) A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocr Metab 81: 3535–3539PubMedGoogle Scholar
  8. Lifton R.P., Dluhy R.G. et al. (1992) A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes Glucocorticoid-remidiable aldosteronism and human hypertension. Nature 355: 262–265PubMedGoogle Scholar
  9. Lin D., Sugawara T. et al. (1995) Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 267: 1828–1831PubMedGoogle Scholar
  10. Mauthe I., Laspe H., Knorr D. (1977) Zur Häufigkeit des kongenitalen adrenogenitalen Syndroms (AGS) München 1963-1972. Klin Padiatr 189: 172–176PubMedGoogle Scholar
  11. Miller W.L. (1988) Molecular biology of steroid hormone synthesis. Endocr Rev 9: 295–318PubMedGoogle Scholar
  12. Miller W.L. (1994) Genetics, diagnosis and management of 21-hydroxylase deficiency. J Clin Endocriniol Metab 78: 241–246Google Scholar
  13. Miller W.L., Auchus R.J., Geiler D.H. (1997) The regulation of 17,20 lyase activity. Steroids 62: 133–142PubMedGoogle Scholar
  14. Morel Y., Miller W.L. (1991) Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv Hum Genet 20: 1–68PubMedGoogle Scholar
  15. New M.I. (1992) Genetic dis orders of adrenal hormone synthesis. Horm Res 37 (Suppl 3):22–33PubMedGoogle Scholar
  16. New M.I. (1994) 21-Hydroxylase deficiency congenital adrenal hyperplasia. J Steroid Biochem Molec Biol 48: 15–22PubMedGoogle Scholar
  17. Pang S. (1997) Congenital adrenal hyperplasia. Bailliere’s Clin Obstet Gynacol 11: 281–306Google Scholar
  18. Pang S. (1997) Congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 26: 853–891PubMedGoogle Scholar
  19. Pang S., Shook M.K. (1997) Current status of neonatal sereening for congenital adrenal hyperplasia. Curr Opin Pediatr 9: 419–423PubMedGoogle Scholar
  20. Prader A. (1958) Vollkommen männliche äußere Genitalentwicklung und Salzverlustsyndrom bei Mädchen mit kongenitalem adrenogenitalem Syndrom. Helv Pediatr Acta 1: 5–15Google Scholar
  21. Sakkal A.H., Zhang L. (1996) Studies of 3ß-hydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased adrenocorticotropin-stimulated delta 5-steroid levels. J Clin Endocr Metab 81: 3961–3965Google Scholar
  22. Schmidt-Matthiesen H., Hepp H. (1998) Gynäkologie und Geburtshilfe. Schattauer, StuttgartGoogle Scholar
  23. Silbernagl A., Despopoulus (1983) Taschenatlas der Physiologie. 2. Aufl. Thieme, Stuttgarl New YorkGoogle Scholar
  24. Simard J., Rheaume E. et al. (1993) Molecular basis of congenital adrenal hyperplasia due to 3ß-hydroxysteroid dehydrogenase deficiency. Mol Endocr 7: 716–728Google Scholar
  25. Speiser P.W., Dupont J. et al. (1992) Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Inverst 90: 584–595Google Scholar
  26. Speiser P.W., New M.I. (1994) Prenatal diagnosis and treatment of cungenital badrenal hyperplasia. J Pediatr Endocrinol 7: 183–191PubMedGoogle Scholar
  27. Stocco D.M., Clark B.J. (1997) The role of steroidogenic acute regulatory pro tein in adrenal and gonadal steroidogenesis. Steroids 62: 29–36PubMedGoogle Scholar
  28. White P.C., Cumow K.M., Pascoe L. (1994) Disorders of steroid 11ß-hydroxylase isozymes. Endocr Rev 15: 421–438PubMedGoogle Scholar
  29. Wilson R.C., Mercado A.B., Cheng K.C., New M.I. (1995) Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 80: 2322–2329PubMedGoogle Scholar
  30. Yanase T., Simpson E.R., Waterinan M.R. (1991) 17a-hydroxylase/ 17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev 12: 91–108PubMedGoogle Scholar
  31. Zachmann M., Tassinari D., Prader A. (1983) Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 ß-hydroxylase deficiency. J Clin Endocr Metab 56: 222–229PubMedGoogle Scholar

Literatur zu Abschn. 5.74

  1. Bergfeld W.F. (1979) Diffuser Haarausfall bei Frauen. In: Orfanos C.E. (Hrsg) Haar und Haarkrankheiten. Fischer, Stuttgart, S 493–503Google Scholar
  2. Bergfeld W.F. (1995) Androgenetic alopecia: an autosomal dominant disorder. Am J Med 98: 95S–98SPubMedGoogle Scholar
  3. Ebling F.J.G. (1986) Hair follicles and associated glands as androgen targets. Clin Endocrinol Metab 15: 319–339PubMedGoogle Scholar
  4. Freinkel R., Freinkel N. (1972) Hair growth in hypothyreoidism. Arch Dermatol 106: 349–352PubMedGoogle Scholar
  5. Gerhard I. (1992) Erst ausschwemmen, dann Dauer-Prophylaxe. In: Medical Tribune 22: 37Google Scholar
  6. Headington J. (1984) Transverse microscopic anatomy of the human scalp. Arch Dermatol 120: 449–456PubMedGoogle Scholar
  7. Klobusch J., Rabe T., Gerhard I., Runnebaum B. (1992) Alopezie und Umweltbelastungen. Klin Lab 38: 469–476Google Scholar
  8. Laue L., Merke D.P., Jones J.V., Bames K.M., Hili S., Cutler G.B. Jr. (1996) A preliminary study of flutamide, testolactone and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 81(10):3535–3539PubMedGoogle Scholar
  9. Ludwig E. (1977a) Androgenetische Alopezie. Arch Dermatol 113: 109PubMedGoogle Scholar
  10. Ludwig E. (1977b) Classification of types of androgenetic alopecia (common baldness) occuring in the female sex. Br J Dermatol 97: 247–254PubMedGoogle Scholar
  11. Maguire H.C., Kligman A.M. (1964) Hair plucking as a diagnostic test. J Invest Dermatol 43: 77–80Google Scholar
  12. Orfanos C.E. (1990) Androgenetic alopecia: Clinical aspects and treatment. In: Orfanos C.E., Happle R. (Hrsg) Hair and Hair Diseases. Springer, Berlin Heidelberg New York Tokyo, pp 485–521Google Scholar
  13. Salomon T. (1968) Genetic factors on male alopecia. In: Baccaredda-Boy A., Morretti G., Frey J.R. (Hrsg) Biopathology of pattern alopecia. Karger, Basel, S 39–49Google Scholar
  14. Sawaya M.E., Price V.H. (1997) Different levels of 5 a-reductase type 1 and 11, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 109: 296–300PubMedGoogle Scholar
  15. Schurz B., Schmidt J.B., Merka M., Huber J.C. (1986) Zur klinischen Bedeutung des TRH-Tests bei der Sterilitätsabklärung und beim androgenetischen Effluvium. Gynakol Rundsch 26 (Suppl 2):195–198Google Scholar
  16. Tronnier H., Essig F. (1976) Zur internen Therapie des Haarausfalles. Acta Dermatol 2: 147–154Google Scholar
  17. Venning V.A., Dawber R.P.R. (1988) Patterned androgenic alopecia in women. J Am Acad Dermatul 18: 1073–1077Google Scholar
  18. Verbow J.L. (1978) Common baldness occuring in females only in one generation. Brit J Clin Pract 32: 261–262Google Scholar
  19. Zaun H., Perret C. (1990) Intemal diseases affecting hair growth. In: Orfanos C.E., Happle R. (ed) Hair and Hair Diseases. Springer, Berlin Heidelberg New York Tokyo, pp 587–600Google Scholar

Literatur zu Abschn. 5.75

  1. Axelrod L.R., Goldzieher J.W. (1962) The polycystic ovary. III. Steroid biosynthesis in normal and polycystic ovarian tissue. J Clin Endocrinol Metab 22: 359–368Google Scholar
  2. Burghen G.A., Givens J.R., Kitabchi A.E. (1980) Correlation of hyperandrogenism with hyperinsulinemia in polycystic ovarian disease. J Clin Endocrinoi Metab 50: 113Google Scholar
  3. Chang R.J., Geffner M.E. (1985) Associated nonovarian problems of polycystic ovarian disease: insulin resistance. Clin Obstet Gynecol 12: 675–685Google Scholar
  4. Chang R.J., Nakamura R.M., Judd H.L., Kaplan S.A. (1983) Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57: 356–359PubMedGoogle Scholar
  5. Erickson G.F., Case E. (1983) Epidermal growth faetor antagonizes ovarian theea-interstitial eytodifferentiation. Mol Cell Endocrinol 31: 71–76PubMedGoogle Scholar
  6. Goldzieher J.W., Green J.A. (1962) The polyzystie ovary. I. Clinical and histologie features. J Clin Endocrinol Metabol 22: 325–335Google Scholar
  7. Kahn C.R., Flier J.S., Bar R.S., Areher J.A., Gorden P., Marhn M.M., Roth J. (1976) The syndromes of insulin resistanee and aeanthosis nigricans. N Engl J Med 294: 739–747PubMedGoogle Scholar
  8. Laatikainen T.J., Apter D.L., Paavonen J.A., Wahlstrom T.R. (1980) Steroids in ovarian and peripheral venous blood in polyeystie ovarian disease. Clin Endocrinol 13: 125–134Google Scholar
  9. Pasquali R., Casimirri F., Venturoli S. et al. (1983) Insulin resistanee in patients with polyeystie ovaries: its relationship to bodyweight and androgen levels. Aeta Endocrinol (Copenh) 104: 110–116Google Scholar
  10. Pasquali R., Fabbri R., Venturoli S., Paradisi R., Antenucci D., Melchionda N. (1986) Effeet of weight loss and antiandrogenie therapy on sex hormone blood levels and insulin resistanee in obese patients with polyeystic ovaries. Am J Obstet Gynecol 154: 139–144PubMedGoogle Scholar
  11. Short R.V. (1962) Further observations on the defective synthesis of ovarian steroids in the Stein-Leventhal syndrome. J Endocrinol 24: 359–368PubMedGoogle Scholar
  12. Short R.V., London D.R. (1961) Defective synthesis of ovarian steroids in the Stein-Leventhal syndrome. BMJ 1: 1724–1731PubMedGoogle Scholar
  13. Shoupe D., Lobo R.A. (1984) The intluence of androgens on insulin resistance. Fertil Steril 41: 385–388PubMedGoogle Scholar
  14. Smith S., Ravniear V.A., Barbieri R.L. (1987) Androgen and insulin response to an oral glucose challenge in hyperandrogenie women. Fertil Steril 48: 72–77PubMedGoogle Scholar
  15. Smith K.D., Steinberger E., Perioff W.H. (1965) Polycystic ovarian disease. Areport of 301 patients. Am J Obstet Gynecol 93: 994–1004PubMedGoogle Scholar
  16. Stuart C.A., Peters E.J., Prince M.J., Richards G., Cavallo A., Meyer W.J. (1986) Insulin resistance with acanthosis nigricans: the roles of obesity and androgen exeess. Metabolism 13: 197–204Google Scholar

Literatur zu Abschn. 5.76

  1. Abs R., Parizel P.M., Beckers A. (1991) Acute effects of Parlodel LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma. J Endocrinol Invest 14: 135–138PubMedGoogle Scholar
  2. Katznelson I., Alexander J.M., Bikkal H.A., Jameson J.L., Klibanski A. (1992) Imbalanced follicie-stimulating hormone betasubunit hormone biosynthesis in human pituitary adenomas. J Clin Endocrinol Metab 74: 1343–1351PubMedGoogle Scholar
  3. Kontogeorgos G., Kovacs K., Horvath E., Scheithauer B.W. (1993) Null cell adenomas, oncocytomas, and gonadotroph adenomas of the human pituitary: an immunocytochemical and ultrastructural analysis of 300 cases. Endocr Pathol 4: 20–27Google Scholar
  4. Kovacs K., Horvath E., Rewcastle N.B., Ezrin C. (1980) Gonadotroph cell adenoma of the pituitary in a woman with longstanding hypogonadism. Arch Gynecol 229: 57–65PubMedGoogle Scholar
  5. Kovacs K., Horvath E., Ryan N., Ezrin C. (1980) Null cell adenomas of the human pituitary. Virchows Arch (A) 387: 165–174Google Scholar
  6. Kovacs K., Asa S.L., Horvath E. (1991) Cytogenesis of non-functioning pituitary adenoma (abstract). Endocr Pathol 2: 177–179Google Scholar
  7. Lamberts S.W., Verleun T., Oosterom R., Hotland L., van Ginkel L.A., Loeber J.G., van Vroonhoven C.C., Stefanko S.Z., de Jong F.H. (1987) The effects of bromocriptine, Thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro. J Clin Endocrinol Metab 64: 524–30PubMedGoogle Scholar
  8. Mermillion J.A., Gatchair-Rose A., Svec F. (1995) Pituitary Tumor and low gonadotropins in a patient with Turner’s Syndrome. J State Med Soc 147: 540–543Google Scholar
  9. Nicolis G., Shimshi M., Allen C., Halmi N.S., Kourides I.A. (1988) Gonadotropin-producing pituitary adenoma in a man with long-standing primary hypogonadismn. J Clin Endocrinol Metab 66: 237–241PubMedGoogle Scholar
  10. Polkowska J., Berault A., Hurbain-Kosmath I., Jolly G., Jutisz M. (1991) Bihormonal celle producing gonadotropins and prolactin in a rat pituitary tumor cell line (RC-4B/C). Neuroendocrinology 54: 267–273PubMedGoogle Scholar
  11. Samaan N.A.; Stepanas A.V., Danziger J., Trujillo J. (1979) Reactive pituitary abnormalities in patients with Klinefelter’s and Turner’s Syndromes. Arch Intern Med 139: 198–201PubMedGoogle Scholar
  12. Sano T., Yamada S. (1994) Histologie and immunohistochemical study of clinically nonfunctioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathol Int 44: 697–703PubMedGoogle Scholar
  13. Sassolas G., Lejeune H., Trouillas J., Forest M.G., Claustrat B., Lahlou N., Loras B. (1988) Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 67: 180–185PubMedGoogle Scholar
  14. Spertini F., Deruaz J.P., Perentes E., Pelet B., Gomez F. (1986) Luteinizing hormone (LH) and prolactin-releasing pituitary tumor: possible malignant transformation of the LH cell line. J Clin Endocrinol Metab 62: 849–854PubMedGoogle Scholar
  15. Vance M.L., Ridgway E.C., Thorner M.O. (1985) Follicle-stimulating hormone—and alphasubunit-secreting pituitary tumor treated with bromocriptine. J Clin Endocrinol Metab 61: 580–584PubMedGoogle Scholar
  16. Young W.F. Jr., Scheithauer B.W., Kovaes K.T., Horvath E., Davis D.H., Randall R.V. (1996) Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 eases. Mayo Clin Proc 71: 649–656PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • C. v. Hagens
  • U. Heinrich
  • F. Kiesewetter
  • T. Rabe
  • B. Runnebaum
  • E. Schulze
  • E. Vladescu

There are no affiliations available

Personalised recommendations